NCT02362464 2024-12-10
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
7 trialsNCT02362451 2022-03-18
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02538341 2021-11-23
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
University of Alabama at Birmingham
Phase 2 Completed
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02566265 2019-01-30
SHIVERING 2
Yale University
Phase 2 Completed
NCT00654030 2018-04-09
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
University of Kentucky
Phase 2 Completed
NCT01205581 2016-09-23
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
St. Jude Children's Research Hospital
Phase 2 Completed